{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:57:44Z","timestamp":1791449864479,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40290-026-00632-y","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:54:59Z","timestamp":1789376099000},"page":"457-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Compliance to Strategic Partner: The Transformation of Regulatory Affairs in AstraZeneca Local Affiliates"],"prefix":"10.1007","volume":"40","author":[{"given":"Mar\u00eda Cristina","family":"Fern\u00e1ndez Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannie","family":"de Munnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Sondej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8636-5733","authenticated-orcid":false,"given":"Ana","family":"P\u00e9rez Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"632_CR1","unstructured":"MAPS Visionary Working Group. The Future of Medical Affairs 2030. Medical Affairs Professional Society [Internet] 2022. https:\/\/medicalaffairs.org\/position-paper-future-medical-affairs-2030\/. Accessed 24 July 2025."},{"key":"632_CR2","unstructured":"Algazy J, Garcia A, Ryan S, Westra A, Zemp A. A vision for medical affairs 2030: Five priorities for patient impact. McKinsey & Company [Internet] 2023. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/a-vision-for-medical-affairs-2030-five-priorities-for-patient-impact#\/. Accessed 27 June 2025."},{"key":"632_CR3","doi-asserted-by":"publisher","unstructured":"P\u00e9rez Dom\u00ednguez A, Marinich J, Monteagudo G, Moreno C, Regadera L, Iglesias I. Pioneering the future of Medical Affairs: a strategic transformation to meet the spanish healthcare ecosystem's evolving trends. Pharmaceut Med. 2025. https:\/\/doi.org\/10.1007\/s40290-025-00574-x. (Epub 20250712)","DOI":"10.1007\/s40290-025-00574-x"},{"key":"632_CR4","doi-asserted-by":"publisher","unstructured":"Medina J, S\u00e1nchez-Covisa J, Nuevo J, Palacios B, Roncero A, Alegr\u00eda M, et al. Utilization of evidence blueprint initiative to transform capability development in AstraZeneca Spain. Pharmaceut Med. 2025. https:\/\/doi.org\/10.1007\/s40290-025-00575-w. (Epub 20250721)","DOI":"10.1007\/s40290-025-00575-w"},{"key":"632_CR5","unstructured":"European Commission. Choose Europe for life sciences - A strategy to position the EU as the world\u2019s most attractive place for life sciences by 2030. Brussels, [Internet] 2025; https:\/\/research-and-innovation.ec.europa.eu\/document\/download\/411698e8-6062-41af-96e5-af54474d70f5_en. Accessed 31 July 2025."},{"key":"632_CR6","unstructured":"Propharma. European Pharma Regulations: 2024 review and 2025 trends to watch. [Internet] 2025. https:\/\/www.propharmagroup.com\/thought-leadership\/european-pharmaceutical-regulations-2024-review-trends-to-watch\/. Accessed 31 July 2025."},{"key":"632_CR7","unstructured":"Syner-G BioPharma Group. The strategic role of regulatory affairs in the pharmaceutical industry [Internet] 2025. https:\/\/synergbiopharma.com\/role-regulatory-affairs-in-pharmaceutical-industry. Accessed 1 Aug 2025."},{"key":"632_CR8","unstructured":"European Federation of Pharmaceutical Industries and Associations. ADDRESSING HEALTHCARE CHALLENGES. Novel Pricing and Payment Models: New solutions to improve patient access [Internet] 2020; https:\/\/www.efpia.eu\/media\/554543\/novel-pricing-and-payment-models-new-solutions-to-improve-patient-access-300630.pdf. Accessed 1 Aug 2025."},{"issue":"3","key":"632_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.clinthera.2023.12.006","volume":"46","author":"C Hey","year":"2024","unstructured":"Hey C, Hunter A, Muller M, Roux NL, Bennett S, Nowok K, et al. A future European scientific dialogue regulatory framework: connecting the dots. Clin Ther. 2024;46(3):293\u20139. https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.006. (Epub 20240115).","journal-title":"Clin Ther"},{"key":"632_CR10","unstructured":"European Commission. New Regulations - Medical Devices regulations. [Internet] 2017. https:\/\/health.ec.europa.eu\/medical-devices-sector\/new-regulations_en. Accessed 21 Oct 2025."},{"issue":"1","key":"632_CR11","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1017\/s0266462323000144","volume":"39","author":"T Wang","year":"2023","unstructured":"Wang T, McAuslane N, Goettsch WG, Leufkens HGM, De Bruin ML. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement. Int J Technol Assess Health Care. 2023;39(1):e20. https:\/\/doi.org\/10.1017\/s0266462323000144. (Epub 20230411).","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"632_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40264-023-01386-1","volume":"47","author":"WW Yang","year":"2024","unstructured":"Yang WW, Juan YC, Wu GH, Pwu RF. The critical intersect of regulations, health technology assessment, and drug safety assessments. Drug Saf. 2024;47(4):289\u201399. https:\/\/doi.org\/10.1007\/s40264-023-01386-1. (Epub 20231219).","journal-title":"Drug Saf"},{"issue":"1","key":"632_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s41120-025-00113-7","volume":"11","author":"K Ahluwalia","year":"2025","unstructured":"Ahluwalia K, Abernathy MJ, Algorri M, Cauchon NS, Perico-Norred NM, Youssef RYA. The future of regulatory filings: digitalization. AAPS Open. 2025;11(1):9. https:\/\/doi.org\/10.1186\/s41120-025-00113-7.","journal-title":"AAPS Open"},{"key":"632_CR14","unstructured":"European Parliament. REGULATION (EU) 2024\/1689 (Artificial Intelligence Act). [Internet] 2024; https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=OJ:L_202401689. Accessed 31 July 2025."},{"key":"632_CR15","unstructured":"European Federation of Pharmaceutical Industries and Associations. EFPIA position on the use of artificial intelligence in the medicinal product lifecycle. [Internet] 2024; https:\/\/efpia.eu\/media\/tzeavw1t\/efpia-position-on-the-use-of-artificial-intelligence-in-the-medicinal-product-lifecycle.pdf. Accessed 31 July 2025."},{"issue":"10","key":"632_CR16","volume":"20","author":"JD van Klaveren","year":"2023","unstructured":"van Klaveren JD, Kruisselbrink JW, van der Voet H, Engel J, van Voorthuijsen T, van Lenthe MS, et al. The MCRA platform for EU regulatory actions: governance, user guidance and FAIRification. EFSA Support Publ. 2023;20(10):8251E.","journal-title":"EFSA Support Publ"},{"key":"632_CR17","doi-asserted-by":"publisher","unstructured":"Leal Beckouche M, Resler Plat G, Marinich JA, Moreno C, Moreno M, Gostkorzewicz J, et al. The evolution of Medical Affairs central teams: shaping strategic action and driving healthcare transformation through scientific interaction. Pharmaceut Med. 2026; 40(1):9-18. https:\/\/doi.org\/10.1007\/s40290-025-00592-9. (Epub 20251105).","DOI":"10.1007\/s40290-025-00592-9"},{"key":"632_CR18","unstructured":"Voisin Consulting Life Sciences. Patient centricity: The foundation of modern healthcare through meaningful engagement [Internet] 2025; https:\/\/voisinconsulting.com\/blog\/patient-centricity-the-foundation-of-modern-healthcare-through-meaningful-engagement\/. Accessed 1 Aug 2025"},{"key":"632_CR19","unstructured":"Freyr. The rise of patient-centric regulatory approaches: balancing innovation and safety. [Internet] 2025; https:\/\/www.freyrsolutions.com\/blog\/the-rise-of-patient-centric-regulatory-approaches-balancing-innovation-and-safety. Accessed 5 Aug 2025."},{"issue":"2","key":"632_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40290-020-00372-7","volume":"35","author":"M Bujar","year":"2021","unstructured":"Bujar M, McAuslane N, Liberti L. The qualitative value of facilitated regulatory pathways in Europe, USA, and Japan: benefits, barriers to utilisation, and suggested solutions. Pharmaceut Med. 2021;35(2):113\u201322. https:\/\/doi.org\/10.1007\/s40290-020-00372-7. (Epub 20210204).","journal-title":"Pharmaceut Med."},{"key":"632_CR21","doi-asserted-by":"publisher","unstructured":"Ajmal CS, Yerram S, Abishek V, Nizam VPM, Aglave G, Patnam JD, et al. Innovative approaches in regulatory affairs: leveraging artificial intelligence and machine learning for efficient compliance and decision-making. AAPS J. 2025;27(1):22. https:\/\/doi.org\/10.1208\/s12248-024-01006-5.","DOI":"10.1208\/s12248-024-01006-5"},{"key":"632_CR22","unstructured":"European Commission. Joint Clinical Assessments [Internet] 2021; https:\/\/health.ec.europa.eu\/health-technology-assessment\/implementation-regulation-health-technology-assessment\/joint-clinical-assessments_en. Accessed 22 Aug 2025."},{"key":"632_CR23","unstructured":"European Commission. Implementation of the Regulation on health technology assessment [Internet] 2022; https:\/\/health.ec.europa.eu\/health-technology-assessment\/implementation-regulation-health-technology-assessment_en. Accessed 22 Aug 2025."},{"key":"632_CR24","unstructured":"European Medicines Agency (EMA). Data Analysis and Real World Interrogation Network (DARWIN EU) [Internet] 2021; https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/data-regulation-big-data-other-sources\/real-world-evidence\/data-analysis-real-world-interrogation-network-darwin-eu. Accessed 22 Aug 2025."},{"key":"632_CR25","unstructured":"European Medicines Agency (EMA). Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle [Internet] 2024; https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf. Accessed 22 Aug 2025."},{"key":"632_CR26","unstructured":"U.S. Food and Drug Administration. FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People [Internet] 2025; https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-agency-wide-ai-tool-optimize-performance-american-people. Accessed 22 Aug 2025."},{"key":"632_CR27","unstructured":"European Medicines Agency (EMA). AI tools and technology - Scientific Explorer for EU regulators. [Internet] 2024; https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/data-regulation-big-data-other-sources\/artificial-intelligence#ai-tools-and-technology-68369. Accessed 15 Dec 2025."},{"key":"632_CR28","unstructured":"European Medicines Agency (EMA). Guiding principles on the use of large language models in regulatory science and for medicines regulatory activities. [Internet] 2024; https:\/\/www.ema.europa.eu\/en\/documents\/other\/guiding-principles-use-large-language-models-regulatory-science-medicines-regulatory-activities_en.pdf. Accessed 15 Dec 2025."},{"key":"632_CR29","unstructured":"The Objective. Sanidad prepara una IA para ayudarle a decidir qu\u00e9 medicamentos financia. [Internet] 2025. https:\/\/theobjective.com\/economia\/2025-11-17\/sanidad-prepara-ia-financiacion-medicamentos\/. Accessed 15 Dec 2025."},{"key":"632_CR30","unstructured":"Thermo Fisher Scientific PPD. The future of the local Regulatory affiliate: Adjusting to Global strategies, processes and expectations. [Internet] 2018; https:\/\/www.ppd.com\/blog\/the-future-of-the-local-regulatory-affiliate-adjusting-to-global-strategies-processes-and-expectations\/"},{"key":"632_CR31","unstructured":"European Commission. Reform of the EU pharmaceutical legislation. [Internet] 2023; https:\/\/health.ec.europa.eu\/medicinal-products\/legal-framework-governing-medicinal-products-human-use-eu\/reform-eu-pharmaceutical-legislation_en. Accessed 15 Oct 2025."},{"key":"632_CR32","unstructured":"Cencora PharmaLex. MHRA provides details on Windsor Framework for UK medicines. [Internet] 2024; https:\/\/www.pharmalex.com\/thought-leadership\/blogs\/mhra-provides-details-on-windsor-framework-for-uk-medicines\/. Accessed 5 Aug 2025."},{"key":"632_CR33","unstructured":"European Federation of Pharmaceutical Industries and Associations. Supply Chains reshaping - How to respond to a crisis. [Internet] 2022. https:\/\/www.efpia.eu\/news-events\/the-efpia-view\/blog-articles\/supply-chains-reshaping-how-to-respond-to-a-crisis\/. Accessed 5 Aug 2025."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00632-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00632-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00632-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:47:03Z","timestamp":1791449223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00632-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00632-y","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"28 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare being employed by AstraZeneca.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Availability of data and materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conception and design of the study, as well as the investigation and analysis performed. Mar\u00eda Cristina Fern\u00e1ndez Montero wrote the first draft. All authors critically reviewed, edited, and commented on the manuscript until the final version was obtained. All authors read and approved the final version of the manuscript.","order":3,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}